Eleanor Perfetto

Eleanor Perfetto is a Professor of Practice in Sciences and Health Outcomes Research at the University of Maryland School of Pharmacy. She is a pharmacist and health services researcher with extensive experience in federal health policy, patient advocacy, and pharmaceutical industry engagement. Her work bridges clinical research, policy development, and patient-centered outcomes.

• BS and MS in Pharmacy – University of Rhode Island
• PhD in Health Policy and Epidemiology – University of North Carolina School of Public Health

Dr. Perfetto’s research focuses on comparative effectiveness research (CER), patient-centered outcomes research (PCOR), and patient-focused drug development (PFDD). She is deeply involved in improving quality performance measurement and integrating patient-reported outcomes (PROs) into clinical development plans. Her work emphasizes evidence adoption, stakeholder engagement, and regulatory science.

Her recent publications and presentations reflect a strong trend in health outcomes research, with emphasis on CER communication, patient engagement, and policy implications. Topics span from concussion policy in sports to FDA guidance on CER dissemination and economic evaluation in healthcare.

Dr. Perfetto holds leadership roles in key healthcare organizations:

• President, Board of Directors – Sports Legacy Institute
• Board Member – Pharmacy Quality Alliance
• Board Member – Health Industry Forum
• Former committee member – Centers for Medicare & Medicaid Services, National Quality Forum, Center for Medical Technology Policy

She has advised on federal health policy and served in the U.S. Public Health Service as an Indian Health Service pharmacist and senior pharmacoepidemiologist at AHRQ. Her advocacy for patients with head trauma-related dementias has received wide recognition. She has received no formally listed scientific awards in the provided text.

Dr. Perfetto has not advised any named students in the provided materials. She is affiliated with no specific lab or research team mentioned, but her work is closely tied to national policy forums and patient advocacy networks.